Drugs / IK-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00858936 | May 2009 → Apr 2010 | — | Mallinckrodt | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IK-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00858936 ↗ |
| Known as | sodium sulfide | “This clinical trial will investigate the safety and effectiveness of IK-1001 (the liquid form of sodium sulfide) when used in Coronary Artery Bypass Graft (CABG) patients to...” NCT00858936 ↗ |
| Route | Intravenous | “The study drug or placebo will be given as an intravenous infusion (into the vein)” NCT00858936 ↗ |